Skip to main content

NK Cells

Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

  • RegistryNCT07579208
  • PhasePhase 1
  • StatusRecruiting
  • ConditionRecurrent Glioblastoma
  • SponsorM.D. Anderson Cancer Center
How NK Cells worksNCT075792081 min

What the film says

Read the transcript

When glioblastoma comes back, engineered immune cells are among the few new ideas, but two things hold them back: the tumor switches them off, and no one knows the best way in.

The idea: build a natural killer cell that resists the tumor's defenses, and test three routes head to head.

At MD Anderson, donor natural killer cells receive receptors for two glioblastoma markers, IL13Rα2 and EGFRvIII. They secrete interleukin-21 to sustain themselves, and two genes are deleted, the TGF-beta receptor and the steroid receptor, so neither the tumor nor patients' steroids can quiet them. Cells go into the tumor, the ventricles, or an artery; tissue is studied afterward to see which route works best.

Chibawanye Ene leads it. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT07579208

    Recurrent GBM; prior radiation and temozolomide; Dual CAR IL13Rα2 + EGFRvIII; IL-21 secretion; TGF-βR2 and NR3C1 deletions; NR3C1 = glucocorticoid receptor → steroid resistance; Three routes: intra-tumoral, intra-ventricular (Ommaya), intra-arterial; window-of-opportunity design comparing persistence and function in post-treatment specimens (+1 more lines)

The drug

What is being tested.

Primary Objectives 1. To undertake a window of opportunity (WOO) clinical trial to compare the biological endpoints of Dual CAR Dual KO NK cells persistence, immunological phenotype and anti-tumor function after administration of Dual CAR Dual KO NK cells via 3 different routes: intra-tumoral, intra-ventricular or intra-arterial injection. By quantitatively assessing post-treatment specimens, the trial will determine the optimal route of administration of this agent. 2.

To assess the safety of Dual CAR Dual KO NK cells after administration via 3 different routes: intra-tumoral, intra-ventricular or intra-arterial injection. Secondary Objectives 1. To determine response as measured by Response Assessment in Neuro-Oncology (RANO), progression free survival (PFS), time to progression (TTP), and overall survival (OS). 2.

The study

How the trial runs.

To find the best method of administering NK cells in patients with recurrent glioblastoma.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Eligibility Criteria
  • Male or female subjects aged ≥ 18 years.
  • Histologically confirmed supratentorial 2021 World Health Organization recurrent glioblastoma (IDH-wildtype GBM), gliosarcoma, or recurrent IDH-mutant WHO grade 4 astrocytoma, with any prior number of recurrences.
  • Have received prior radiation and temozolomide therapy.
  • Single tumor no larger than 5 cm in its greatest diameter.
  • Karnofsky Performance Status (KPS) score of >70.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.